S*Bio initate Phase I/II trial of JAK2 inhibitor SB1518 in Chronic Idiopathic Myelofibrosis

S*Bio have initated a Phase I/II trial of JAK2 inhibitor SB1518 in Chronic Idiopathic Myelofibrosis diseases including Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera and Essential Thrombocythemia

Servier publish indolocarbazole Chk1 kinase inhibitors

Servier have published a series of rebeccamycin based Checkpoint kinase 1 (Chk1) inhibitors